3Green JR,Muller K,Jageggi KA.Preclinical pharmacology of CGP42446.a new:potent,heterocyclic bisphospbonate compound[J].J Bone Miner Res,1994,9(5):745-751.
4Coleman RE,Pumbit OP,Black C,et al.I bandronate:a well toinerated new oral bisphospbonate for the treatment of bone metastases[J].Breast,1995,4(9):236.
1Rosen C J,Kessenich CR.Conparative clinical pharnacology and therapeutic use of bisphosphonates in metabolic bone diseases[ J].Drug,1996,51 (4):537 ～ 551.
2Green JR,Muller K,Jaeggi K A.Pharmacology of CGP42446.a new,potent,heterocyclic bisphosphonate compound[ J ].J Bone Miner Res,1994,9 (5):745 ～ 751.
3Lucas LK,Lipman AG.Recent advances in pharmacotherapy for cancer pain management[J].Cancer Pract,2002,10 (suppl 1):S14-20.
4Rizzoli R.Bisphosphonates and reduction of skeletal events in patients with bone metastatic breast cancer[J].Ann Oncol,2004,15(5):700-701.
6Body JJ,Diel IJ,Lichinitser MR,et al.Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases[J].Ann Oncol,2003,14(9):1399-1405.
7Tripathy D,Lichinitzer M,Lazarev A,et al.Oral ibandronate for the treatment of metastatic bone disease in breast cancer:efficacy and safety results from a randomized,double-blind,placebo-controlled trial[J].Ann Oncol,2004,15(5):743-750.
8Bell R.Efficacy of ibandronate in metastatic bone disease:review of clinical data[J].Oncologist,2005,10 (suppl 1):8-13.
9Mancini I,Dumon JC,Body JJ.Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease:a pilot study[J].J Clin Oncol,2004,22(17):3587-3592.
10Inoue K,Karashima T,Fukata S,et al.Effect of combination therapy with a novel bisphosphonate,minodronate (YM529),and docetaxel on a model of bone metastasis by human transitional cell carcinoma[J].Clin Cancer Res,2005,11(18):6669-6677.
